These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 8186502)

  • 1. Can dialysis remove protein bound toxins that accumulate because of renal secretory failure?
    Gulyassy PF
    ASAIO J; 1994; 40(1):92-4. PubMed ID: 8186502
    [No Abstract]   [Full Text] [Related]  

  • 2. New approaches to the removal of protein-bound toxins from blood plasma of uremic patients.
    Sarnatskaya VV; Yushko LA; Sakhno LA; Nikolaev VG; Nikolaev AV; Grinenko DV; Mikhalovsky SV
    Artif Cells Blood Substit Immobil Biotechnol; 2007; 35(3):287-308. PubMed ID: 17573628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new procedure for the removal of protein bound drugs and toxins.
    Stange J; Mitzner S; Ramlow W; Gliesche T; Hickstein H; Schmidt R
    ASAIO J; 1993; 39(3):M621-5. PubMed ID: 8268613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of binding by concentrated peritoneal dialysate and serum.
    Gulyassy PF; Depner TA; Shearer GC
    ASAIO J; 1993; 39(3):M569-72. PubMed ID: 8268601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematological changes post-hemo and peritoneal dialysis among renal failure patients in Sudan.
    Mohamed Ali MS; Babiker MA; Merghani LB; Ali FA; Abdulmajeed MH
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):274-9. PubMed ID: 18310883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An albumin-fixed membrane for the removal of protein-bound toxins.
    Ge D; Wu D; Shi W; Ma Y; Tian X; Liang P; Zhang Q
    Biomed Mater; 2006 Sep; 1(3):170-4. PubMed ID: 18458399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes.
    De Smet R; Dhondt A; Eloot S; Galli F; Waterloos MA; Vanholder R
    Nephrol Dial Transplant; 2007 Jul; 22(7):2006-12. PubMed ID: 17468506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomics in extracorporeal blood purification and peritoneal dialysis.
    Thongboonkerd V
    J Proteomics; 2010 Jan; 73(3):521-6. PubMed ID: 19527805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Kidney failure and therapeutic possibilities].
    Krankenpfl J; 1999 Oct; 37(10):389-90. PubMed ID: 10693454
    [No Abstract]   [Full Text] [Related]  

  • 10. Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition.
    de Mutsert R; Grootendorst DC; Indemans F; Boeschoten EW; Krediet RT; Dekker FW;
    J Ren Nutr; 2009 Mar; 19(2):127-35. PubMed ID: 19218039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of levels of serum mineral metabolism markers, albumin and C-reactive protein for treatment costs of patients on maintenance dialysis.
    Salonen T; Piirto J; Reina T; Saha H; Pasternack A
    Nephron Clin Pract; 2007; 106(1):c17-23. PubMed ID: 17347578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro study on the competitive binding of diflunisal and uraemic toxins to serum albumin and human plasma using a potentiometric ion-probe technique.
    Davilas A; Koupparis M; Macheras P; Valsami G
    J Pharm Pharmacol; 2006 Nov; 58(11):1467-74. PubMed ID: 17132209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oral load of the early glycation compound lactuloselysine fails to accumulate in the serum of uraemic patients.
    Schwenger V; Morath C; Schönfelder K; Klein W; Weigel K; Deppisch R; Henle T; Ritz E; Zeier M
    Nephrol Dial Transplant; 2006 Feb; 21(2):383-8. PubMed ID: 16204288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins.
    Stange J; Ramlow W; Mitzner S; Schmidt R; Klinkmann H
    Artif Organs; 1993 Sep; 17(9):809-13. PubMed ID: 8240075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dialysis therapy: 'think differently'.
    Perrone B
    Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v1-2. PubMed ID: 17586840
    [No Abstract]   [Full Text] [Related]  

  • 16. [Can the concentration of middle molecular substances in plasma contribute to the assessment of the adequacy of regular dialysis therapy?].
    Válek A; Spustová V; Lopot F; Erben J; Dzúrik R
    Cas Lek Cesk; 1984 May; 123(20):599-604. PubMed ID: 6467309
    [No Abstract]   [Full Text] [Related]  

  • 17. [5/12. Drugs and the dialysis patient].
    Koutny E; Motte G; Woronoff-Lemsi MC
    Soins; 2001; (657):51-2. PubMed ID: 12008607
    [No Abstract]   [Full Text] [Related]  

  • 18. New biological method for determination of the desintoxication rate of human plasma after dialysis.
    Kovatchev D; Dimitrov H; Hristova P; Nenov D
    Life Support Syst; 1983; 1 Suppl 1():191-4. PubMed ID: 6336408
    [No Abstract]   [Full Text] [Related]  

  • 19. Impaired binding of drugs and endogenous ligands in renal diseases.
    Gulyassy PF; Depner TA
    Am J Kidney Dis; 1983 May; 2(6):578-601. PubMed ID: 6342372
    [No Abstract]   [Full Text] [Related]  

  • 20. Influences of haemodialysis on the binding sites of human serum albumin: possibility of an efficacious administration plan using binding inhibition.
    Nishio T; Takamura N; Nishii R; Tokunaga J; Yoshimoto M; Kawai K
    Nephrol Dial Transplant; 2008 Jul; 23(7):2304-10. PubMed ID: 18390890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.